Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats

@article{Kaji2013DipeptidylPI,
  title={Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats},
  author={Kosuke Kaji and Hitoshi Yoshiji and Yasuhide Ikenaka and Ryuichi Noguchi and Yosuke Aihara and Akitoshi Douhara and Kei Moriya and Hideto Kawaratani and Yusaku Shirai and Junichi Yoshii and Koji Yanase and Mitsuteru Kitade and Tadashi Namisaki and Hiroshi Fukui},
  journal={Journal of Gastroenterology},
  year={2013},
  volume={49},
  pages={481-491}
}
BackgroundDipeptidyl peptidase-4 inhibitor (DPP4-I) is clinically used as a new oral antidiabetic agent. Although DPP4 is reportedly associated with the progression of chronic liver diseases, the effect of DPP4-I on liver fibrosis development is still obscure. This study was designed to elucidate the effect of DPP4-I on liver fibrosis development in conjunction with the activated hepatic stellate cells (Ac-HSCs).MethodsThe antifibrotic effect of DPP4-I was assessed in vivo and in vitro using… Expand
TGR5 Activation Modulates an Inhibitory Effect on Liver Fibrosis Development Mediated by Anagliptin in Diabetic Rats
TLDR
Collectively, TGR5 agonist and DPP-4 inhibitor appears to be a novel strategy against liver fibrosis under diabetic conditions. Expand
Alogliptin alleviates liver fibrosis via suppression of activated hepatic stellate cell.
TLDR
It is demonstrated that negatively modulation of alogliptin on hepatic stellate cell (HSC) activation might contribute to liver fibrosis alleviation and suggests that DPP4 may be a novel target for Liver fibrosis therapy. Expand
Dipeptidyl peptidase IV (DPP-IV) inhibition prevents fibrosis in adipose tissue of obese mice.
TLDR
Vildagliptin prevents fibrosis formation in adipose tissue in obese mice, at least partially through NPY and NPY Y1 receptor activation, and highlights the importance of vildAGliptin in the treatment of fibrosis that occur in obesity. Expand
Combination of Sitagliptin and Silymarin ameliorates liver fibrosis induced by carbon tetrachloride in rats.
TLDR
It is shown that the combination therapy is more beneficial than monotherapy in ameliorating liver fibrosis in rats, and it is suggested that Sitagliptin alone or in combination with Silymarin may introduce a new strategy for treating liver Fibrosis in humans. Expand
Evogliptin, a Dipeptidyl Peptidase-4 Inhibitor, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice
TLDR
It is demonstrated that evogliptin is protective against UUO-induced renal fibrosis, suggesting that its clinical applications could extend to the treatment of kidney disease of non-diabetic origin. Expand
Vildagliptin, a DPP-4 inhibitor, attenuates carbon tetrachloride-induced liver fibrosis by targeting ERK1/2, p38α, and NF-κB signaling.
TLDR
VLD showed a strong trend toward increasing the antioxidant defense machinery of fibrotic tissue, and it was confirmed that GLP-1Rs were not implicated in the observed hepatoprotection. Expand
Alleviation of Carbon-Tetrachloride-Induced Liver Injury and Fibrosis by Betaine Supplementation in Chickens
TLDR
The results highlight the antioxidant ability of betaine, which alleviates CCl4-induced fibrogenesis process along with the suppression of hepatic stellate cells activation, and suggest betaine can be used as a potent nutritional or therapeutic factor for reducing liver fibrosis. Expand
Carvedilol improves liver cirrhosis in rats by inhibiting hepatic stellate cell activation, proliferation, invasion and collagen synthesis
TLDR
Carvedilol may alleviate liver cirrhosis in rats by inhibiting HSC activation, proliferation, invasion and collagen synthesis, and may be a potential treatment of early-stage liver Cirrhosis. Expand
Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis
TLDR
The therapeutic effect of combining an ARB and rifaximin was evaluated along with hepatic fibrogenesis, the lipopolysaccharide–Toll-like receptor 4 (TLR4) regulatory cascade, and intestinal barrier function and showed a stronger inhibitory effect compared to that conferred by a single agent. Expand
Linagliptin-Mediated DPP-4 Inhibition Ameliorates Kidney Fibrosis in Streptozotocin-Induced Diabetic Mice by Inhibiting Endothelial-to-Mesenchymal Transition in a Therapeutic Regimen
TLDR
It is found that the DPP-4 inhibitor linagliptin ameliorated kidney fibrosis in diabetic mice without altering the blood glucose levels associated with the inhibition of EndMT and the restoration of microRNA 29s. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 58 REFERENCES
Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats.
TLDR
In vitro study showed that STI-571 markedly attenuated PDGF-BB-induced proliferation and migration and alpha-SMA and alpha2-(I)-procollagen mRNA of activated HSC in a dose-dependent manner, which may provide an effective new strategy for antifibrosis therapy. Expand
Imatinib Mesylate Improves Liver Regeneration and Attenuates Liver Fibrogenesis in CCL4-Treated Mice
TLDR
STI-571 treatment effectively attenuated liver fibrogenesis and improved in liver regeneration in vivo and induced apoptosis in HSCs both in vitro and in vivo. Expand
Inhibitors of dipeptidyl peptidase IV-like activity mediate antifibrotic effects in normal and keloid-derived skin fibroblasts.
TLDR
Inhibition of DP IV-like enzymatic activity may represent a promising therapeutic approach for the treatment of fibrotic skin disorders and keloid-derived skin fibroblasts in vitro. Expand
Selective aldosterone blocker ameliorates the progression of non-alcoholic steatohepatitis in rats.
TLDR
In vitro study showed that SAB inhibited the Ald-induced HSC proliferation and in vitro angiogenesis in a dose-dependent manner, indicating that Ald plays a pivotal role in the progression of NASH. Expand
The effects of the selective mineralocorticoid receptor antagonist eplerenone on hepatic fibrosis induced by bile duct ligation in rat.
TLDR
Eplerenone attenuated the development of BDL-induced hepatic fibrosis by reducing oxidative stress, suppressing activated hepatic stellate cells and decreasing plasma ATII levels. Expand
Serum dipeptidyl peptidase IV (DPP IV, CD26) activity in chronic hepatitis C.
TLDR
Serum DPP IV activity seems to be an indicator of HCV induced liver injury and may reflect the efficacy of interferon therapy. Expand
Dipeptidyl peptidase activity of CD26 in serum and urine as a marker of cholestasis: experimental and clinical evidence.
TLDR
The results establish CD26-associated serum DPP activity as a novel, clinically useful marker of cholestasis and demonstrate that in contrast with alkaline phosphatase levels, DPP levels do not change in metastatic bone disease. Expand
Angiotensin‐II type 1 receptor interaction is a major regulator for liver fibrosis development in rats
TLDR
The results suggested that the RAS, especially AT‐II and AT1‐R interaction plays a pivotal role in liver fibrosis development through HSC activation, and both CA and PE may provide an effective new strategy for anti–liver fibrosis therapy. Expand
Mechanisms of hepatic fibrogenesis.
TLDR
Clinical and translational implications of these advances have become clear, and have begun to impact significantly on the management and outlook of patients with chronic liver disease. Expand
Dual role of dipeptidyl peptidase IV (DPP IV) in angiogenesis and vascular remodeling.
TLDR
If DPPIV proves to be indeed a critical step required for inhibiting NPY’s contractile and pro-atherosclerotic effect and potentiating its angiogenic activities, abnormally low DPP IV expression and activity could be a risk factor for hypertension and ischemic cardiovascular diseases, in which NPY has already been implicated28. Expand
...
1
2
3
4
5
...